News-Papers
Testimonial
Video Gallery
Melatonin and its contribution to tumor attenuation in systemic malignancies
Published on Thursday, 14 August 2014
Letter To The Editor
See also About Melatonin.
Search
Follow us...
Latest
- Pretreatment with melatonin protects against cyclophosphamide-induced oxidative stress and renal damage in mice
- Melatonin Pharmacological Blood Levels Increase Total Antioxidant Capacity in Critically Ill Patients
- A Review of Biological and Pharmacological Actions of Melatonin: Oxidant and Prooxidant Properties
- Melatonin as Antioxidant Under Pathological Processes
- Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage
- Melatonin as antioxidant, geroprotector and anticarcinogen
- The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor
- Does the use of melatonin overcome drug resistance in cancer chemotherapy?
- Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment
- Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved
- Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review
- Multifaceted Role of Vitamin D in Breast Cancer: A Systematic Review of Genetic and Pathway-Based Mechanisms
- Multifaceted roles of melatonin in oncology: an insight into its therapeutic potential in cancer management
- Nocturnal Melatonin Deficiency in Colorectal Cancer: Independent Predictive Value Beyond Sleep Quality
- Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture
- Melatonin for the Management of Cancer-Related Fatigue in Breast Cancer: An Integrative Review
- Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer
- Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells
Most Read
- The Di Bella Method (DBM)
- About melatonin - 1996
- All-trans-retinoic acid and cancer
- Biography
- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer
- Chronic Lymphocytic Leukemia: 4 patients, long-lasting remission
- Somatostatin in oncology, the overlooked evidences
- Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage
- How effective is chemo therapy?
- Bibliography
- Complete objective response to biological therapy of plurifocal breast carcinoma
- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report
- Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report
- Vademecum
- Frequently Asked Questions
- Declaration recommends eliminate the use of Impact factor for research evaluation
- Non–Small-Cell Lung Cancer Patients with Low Performance Status: study on 28 patients
- Breast cancer: study on 122 cases. The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer